Novo Nordisk targets -2% to +2% 2026 sales growth at CER while expecting DKK 60B to DKK 70B free cash flow
Tickers: $NVO
Topics: free cash flow guidance sales growth
Read the full article at Seeking Alpha
Part of the story A. O. Smith Reports Flat Q3 2026 Revenue Amid China Divestiture and Rising Input Costs (9 articles)